LEO Science & Tech Hub (The Hub), a research and development unit of LEO Pharma, has initiated 2 collaborative projects with The Wellman Center for Photomedicine at Massachusetts General Hospital.
The Hub, which identifies, develops, and funds innovative solutions that improve the lives of patients with skin diseases, will provide research funding to support development of novel imaging technology using a disposable microbiopsy device. Conor L Evans, PhD, assistant professor, Harvard Medical School, will lead the project. The Evans Lab’s specializes in microscopy and spectroscopy for understanding cancer and dermatology disorders. The research project collaboration will explore novel imagine technologies that will to enable non-invasive, high-resolution, real-time pharmacokinetic/pharmacodynamic measurements with help of the lab’s coherent Raman scattering (CRS) technology (Figure 1).
Figure 1. Coherent Raman imaging may one day allow real-time biological measurements to benefit patients. Here’s an image of mouse skin “tuned” into the vibrational frequencies of lipids taken at the surface of skin and shows hairs and the hexagonally packed corneocytes.
The second project includes work with Walfre Franco, PhD, clinical instructor, and Adam Raff, MD, PhD, clinical associate from R Rox Anderson’s Lab. The Anderson Lab will focus on discovering new optical treatments and diagnostics for dermatologic applications, and will seek to develop a suture-free and disposable microbiopsy device that may allow for a non-scarring sampling procedure of full-thickness skin microbiopsies.
"We are excited to enter these collaborations with the Wellman Center for Photomedicine at Mass General Hospital and are honored to work with scientists at the forefront of imaging technology and microbiopsy research,” said Michael Sierra, PhD, VP, The Hub. “At LEO Science & Tech Hub, we firmly believe in the power of collective effort and are always seeking cutting-edge technologies to advance non-invasive biopsy and imaging technologies for patients with skin diseases.”
—Julie Gould (Mazurkiewicz)
LEO Science & Tech Hub (The Hub), a research and development unit of LEO Pharma, has initiated 2 collaborative projects with The Wellman Center for Photomedicine at Massachusetts General Hospital.
The Hub, which identifies, develops, and funds innovative solutions that improve the lives of patients with skin diseases, will provide research funding to support development of novel imaging technology using a disposable microbiopsy device. Conor L Evans, PhD, assistant professor, Harvard Medical School, will lead the project. The Evans Lab’s specializes in microscopy and spectroscopy for understanding cancer and dermatology disorders. The research project collaboration will explore novel imagine technologies that will to enable non-invasive, high-resolution, real-time pharmacokinetic/pharmacodynamic measurements with help of the lab’s coherent Raman scattering (CRS) technology (Figure 1).
Figure 1. Coherent Raman imaging may one day allow real-time biological measurements to benefit patients. Here’s an image of mouse skin “tuned” into the vibrational frequencies of lipids taken at the surface of skin and shows hairs and the hexagonally packed corneocytes.
The second project includes work with Walfre Franco, PhD, clinical instructor, and Adam Raff, MD, PhD, clinical associate from R Rox Anderson’s Lab. The Anderson Lab will focus on discovering new optical treatments and diagnostics for dermatologic applications, and will seek to develop a suture-free and disposable microbiopsy device that may allow for a non-scarring sampling procedure of full-thickness skin microbiopsies.
"We are excited to enter these collaborations with the Wellman Center for Photomedicine at Mass General Hospital and are honored to work with scientists at the forefront of imaging technology and microbiopsy research,” said Michael Sierra, PhD, VP, The Hub. “At LEO Science & Tech Hub, we firmly believe in the power of collective effort and are always seeking cutting-edge technologies to advance non-invasive biopsy and imaging technologies for patients with skin diseases.”
—Julie Gould (Mazurkiewicz)
LEO Science & Tech Hub (The Hub), a research and development unit of LEO Pharma, has initiated 2 collaborative projects with The Wellman Center for Photomedicine at Massachusetts General Hospital.
The Hub, which identifies, develops, and funds innovative solutions that improve the lives of patients with skin diseases, will provide research funding to support development of novel imaging technology using a disposable microbiopsy device. Conor L Evans, PhD, assistant professor, Harvard Medical School, will lead the project. The Evans Lab’s specializes in microscopy and spectroscopy for understanding cancer and dermatology disorders. The research project collaboration will explore novel imagine technologies that will to enable non-invasive, high-resolution, real-time pharmacokinetic/pharmacodynamic measurements with help of the lab’s coherent Raman scattering (CRS) technology (Figure 1).
Figure 1. Coherent Raman imaging may one day allow real-time biological measurements to benefit patients. Here’s an image of mouse skin “tuned” into the vibrational frequencies of lipids taken at the surface of skin and shows hairs and the hexagonally packed corneocytes.
The second project includes work with Walfre Franco, PhD, clinical instructor, and Adam Raff, MD, PhD, clinical associate from R Rox Anderson’s Lab. The Anderson Lab will focus on discovering new optical treatments and diagnostics for dermatologic applications, and will seek to develop a suture-free and disposable microbiopsy device that may allow for a non-scarring sampling procedure of full-thickness skin microbiopsies.
"We are excited to enter these collaborations with the Wellman Center for Photomedicine at Mass General Hospital and are honored to work with scientists at the forefront of imaging technology and microbiopsy research,” said Michael Sierra, PhD, VP, The Hub. “At LEO Science & Tech Hub, we firmly believe in the power of collective effort and are always seeking cutting-edge technologies to advance non-invasive biopsy and imaging technologies for patients with skin diseases.”
Dr Joseph F Merola, MD, MMSc and Dr Alexis Ogdie, MD, MSCE got together to discuss combined clinics touched base on “accessing the role of interdisciplinary care in optimizing disease outcomes and then understanding how combined approaches to...
Dr Joseph F Merola, MD, MMSc and Dr Alexis Ogdie, MD, MSCE got together to discuss combined clinics touched base on “accessing the role of interdisciplinary care in optimizing disease outcomes and then understanding how combined approaches to...
The average cost of developing a new prescription drug is $897 million, almost four times the cost in the early 1990s, according to a study by the Tufts Center for the Study of Drug Development, Bloomberg/Bern Record reports. Results of the...
The average cost of developing a new prescription drug is $897 million, almost four times the cost in the early 1990s, according to a study by the Tufts Center for the Study of Drug Development, Bloomberg/Bern Record reports. Results of the...
During his session presented at Dermatology Week 2022, Brett King, MD, PhD, discussed the lack of effective treatment for alopecia areata, and recent data on utilizing JAK inhibitors.
During his session presented at Dermatology Week 2022, Brett King, MD, PhD, discussed the lack of effective treatment for alopecia areata, and recent data on utilizing JAK inhibitors.
E ach year, you and your colleagues will diagnose more than 150,000 patients with new cases of psoriasis — 20,000 of these patients will be children, according to the American Academy of Dermatology (AAD). For the more than 7 million...
E ach year, you and your colleagues will diagnose more than 150,000 patients with new cases of psoriasis — 20,000 of these patients will be children, according to the American Academy of Dermatology (AAD). For the more than 7 million...
1. What alternative therapies does Dr Swanson suggest for children who have difficulty adhering to topical treatment regimens?a) Antibioticsb) Injectable or oral medicationsc) UV light therapyd) Homeopathic remedies2. According to Dr Swanson,...
1. What alternative therapies does Dr Swanson suggest for children who have difficulty adhering to topical treatment regimens?a) Antibioticsb) Injectable or oral medicationsc) UV light therapyd) Homeopathic remedies2. According to Dr Swanson,...
1. According to Dr Linda Stein Gold, how do nonsteroidal topical therapies compare to traditional steroid-based treatments for managing psoriasis and AD?a) They are less effective but safer.b) They are as effective as mid-potency steroids and...
1. According to Dr Linda Stein Gold, how do nonsteroidal topical therapies compare to traditional steroid-based treatments for managing psoriasis and AD?a) They are less effective but safer.b) They are as effective as mid-potency steroids and...
According to a recent interview with Jessica Johnson, MPH, what is a significant barrier to seeking mental health support among patients with atopic dermatitis?
According to a recent interview with Jessica Johnson, MPH, what is a significant barrier to seeking mental health support among patients with atopic dermatitis?
Which class of medications received a "general thumbs up" in the latest guidelines for atopic dermatitis management due to their efficacy and low cancer risk?
Which class of medications received a "general thumbs up" in the latest guidelines for atopic dermatitis management due to their efficacy and low cancer risk?
